Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | BioPolaris

Diabetes R and D Pipeline: PPAR Agonists
PPAR (peroxisome proliferator-activated receptor) agonists are insulin sensitizers and lipid metabolism modifying compounds.

PPARs are a nuclear receptor superfamily with four subtypes designated as PPARa (alpha), PPAR?1 (gamma1), PPAR?2 (gamma2), and PPARd (delta). Among them, especially PPAR gamma receptors, and their agonists, have a major role in adipogenesis, insulin sensitivity and glucose and lipid metabolism.

Diabetes R and D Pipeline: GLP-1 Agonists and Analogs
GLP-1 agonist and analogs are insulin secretagouge compounds. GLP-1 (glucagon-like peptide 1) is a potent glucoregulatory incretin hormone that lowers blood glucose levels postprandially. It is produced by intestinal L cells and released into circulation in response to ingestion of food, as well as neural and endocrine stimuli. Following its release into blood by intestine, in response to food intake, GLP-1 impacts several organs including intestinal tract where it slows food absorption.

Diabetes: Potential In-Licensing & Out-Licensing R and D Asian Companies<p></p>

Diabetes: Potential In-Licensing & Out-Licensing R and D Asian Companies
Due to increased incidence and prevalence of diabetes in Asian countries, a significant number of Asian pharmaceutical companies are involved in development of new therapeutic compounds for the treatment of diabetes. On the other hand, the economic growth of Asia, particularly China and India, will enable better health care and treatment of their patients, meaning that biopharmaceutical and pharmaceutical markets are coming to a new age.

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions